Loading company
Prokidney Corp.
PROK · Nasdaq · ·
Next earnings: November 9, 2026
$1.64+1.6%Sep 29 close
- 1M
- -10.7%
- 6M
- +0.9%
- 1Y
- -32.4%
- 5Y
- -83.3%
PROK · Nasdaq · ·
Next earnings: November 9, 2026
$1.64+1.6%Sep 29 close
Prokidney Corp. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $150K | $221K | -32.13% |
| Profit | -$28.4M | -$16.6M | -71.71% |
| Free Cash Flow | -$44.2M | -$34.5M | -28.03% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Prokidney Corp. has no earnings call transcript available.
“), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the second quarter ended June 30, 2026, and provided business highlights. “This update marks an important milestone for ProKidney as we have completed enrollment for the PROACT 1 accelerated approval analysis, positioning us for our pivotal eGFR slope topline readout anticipated in the second quarter of 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Corp. ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT ® ), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Prokidney Corp.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.